Guillain-Barre Syndrome Treatments — CPB 0732 | AETNA Coverage Update

Aetna modified CPB 0732 for Guillain-Barré syndrome treatments, effective December 20, 2025. Here's what billing teams need to know about covered therapies, experimental exclusions, and the codes that determine reimbursement.

Aetna, a CVS Health company, updated CPB 0732 to clarify medical necessity criteria for GBS treatments, drawing a hard line between covered therapies — IVIG (CPT 90283, HCPCS J1561, J1566, J1568, J1569), plasmapheresis (CPT 36514), and outpatient pulmonary rehabilitation (HCPCS S9473) — and a long list of experimental treatments that will not get paid. The experimental list includes corticosteroids, rituximab (J9312), eculizumab (J1299), interferons, and 13 other therapies. If your practice treats GBS patients under Aetna plans, this coverage policy directly shapes what you can bill and what you'll need to defend on appeal.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna, a CVS Health company
Policy	Guillain-Barre Syndrome Treatments
Policy Code	CPB 0732
Change Type	Modified
Effective Date	December 20, 2025
Impact Level	Medium — affects neurology, critical care, and infusion billing teams
Specialties Affected	Neurology, Critical Care, Pulmonary Rehabilitation, Infusion Therapy
Key Action	Verify all GBS claims route through CPB 0206 (IVIG) or CPB 0285 (plasmapheresis) before billing — and pull corticosteroid and rituximab claims if GBS is the primary indication

---

Aetna Guillain-Barré Syndrome Coverage Criteria and Medical Necessity Requirements 2025

The Aetna GBS coverage policy under CPB 0732 Aetna system covers three treatment pathways. Each one cross-references a separate Clinical Policy Bulletin with its own criteria. That's the detail most billing teams miss.

IVIG is covered under CPB 0732 when it meets the criteria in CPB 0206 (Parenteral Immunoglobulins). You can't just bill CPT 90283 or HCPCS J1561 with a G61.0 diagnosis and expect it to go clean. Your documentation must satisfy CPB 0206's medical necessity requirements, not just confirm a GBS diagnosis. If your infusion team isn't cross-checking both bulletins before authorizations go in, expect claim denials.

Plasmapheresis follows the same logic. CPT 36514 (therapeutic apheresis for plasma pheresis) is covered when it meets the criteria in CPB 0285. That bulletin governs plasmapheresis and therapeutic apheresis broadly — Aetna uses the same standards regardless of the underlying diagnosis. Prior authorization requirements for plasmapheresis are almost certain for Aetna commercial plans. Confirm prior auth status before scheduling.

Outpatient pulmonary rehabilitation is covered under HCPCS S9473 when it meets the criteria in CPB 0032. GBS can cause respiratory muscle weakness that requires pulmonary rehab — this is a legitimate billing pathway for recovering patients. But again, the criteria in CPB 0032 apply. Documenting "GBS with respiratory involvement" isn't enough on its own. Your pulmonary rehab team needs to show they've met the specific program criteria Aetna requires.

The cross-referencing structure here is a real compliance risk. Three covered treatments, three separate policy bulletins, and one primary code — G61.0. Make sure your billing guidelines account for all three upstream policies, not just CPB 0732.

---

Aetna Guillain-Barré Syndrome Exclusions and Non-Covered Indications

Aetna's experimental designation list for GBS is longer than most. Thirteen therapies are explicitly classified as experimental, investigational, or unproven. That classification means no reimbursement — and an appeal based on clinical evidence alone is a steep hill to climb.

The biggest financial risk here is corticosteroids. Multiple HCPCS codes cover injectable and oral steroids — J0702, J1020, J1030, J1040, J1094, J1100, J1700, J1710, J1720, J2650, J2920, J2930, J3300, J3301, J3302, J3303, J7509, J7510, J7512, J8540. If your physicians order corticosteroids as part of GBS management and G61.0 is the primary ICD-10 code on the claim, Aetna will deny it. Corticosteroids aren't just non-preferred — they're explicitly experimental under this policy.

Rituximab (J9312) appears on the list, which matters for practices treating refractory GBS. So does eculizumab (J1299). Both carry significant per-unit costs, and a denial on either is a large write-off.

Interferons are excluded across multiple HCPCS codes — J9212, J9213, J9214, J9215, J9216, Q3027, S9559. If you're billing interferon products for any GBS-coded patient, those claims are at risk under this policy.

Acupuncture (CPT 97810–97814, HCPCS S8930) is also experimental for GBS. That's consistent with most payer positions on acupuncture for neurological conditions.

The remaining experimental therapies — amantadine, Bifidobacterium infantis, brain-derived neurotrophic factor, cerebrospinal fluid filtration, leukocyte trafficking inhibitors (J2323 for natalizumab, J3380 for vedolizumab, Q5134 for natalizumab biosimilar), neuromuscular electrical stimulation, per-oral endoscopic myotomy for GBS-associated achalasia, and sugammadex — round out the list. Some of these don't have specific HCPCS codes under this policy, so billing them with GBS as the primary indication creates claim-level ambiguity. Talk to your compliance officer before submitting any of these.

---

Coverage Indications at a Glance

---

Aetna Guillain-Barré Syndrome Billing Guidelines and Action Items 2025

These are the steps your billing and RCM team should take before and after the December 20, 2025 effective date.

Copy Action Items

---

CPT, HCPCS, and ICD-10 Codes for Guillain-Barré Syndrome Treatments Under CPB 0732

Covered CPT Codes (When Selection Criteria Are Met)

Code	Type	Description Copy
36514	CPT	Therapeutic apheresis; for plasma pheresis
90283	CPT	Immune globulin (IgIV), human, for intravenous use

Covered HCPCS Codes (When Selection Criteria Are Met)

Experimental / Not Covered CPT Codes

Experimental / Not Covered HCPCS Codes

Key ICD-10-CM Diagnosis Code

Code	Description Copy
G61.0	Guillain-Barré syndrome

---